Institute of Health and
Biomedical Innovation


10 April 2017

Submit your EOI by April 28 to be part of the The Bridge Program: face-to-face and online training in the scientific, legal, financial, clinical, regulatory and reimbursement disciplines that contribute to research translation and the commercialisation of medicines.

QUT and Medical Technologies and Pharmaceutical Growth Centre (MTPConnect) together with a consortium of 14 partners including global pharmaceutical companies, venture capitalists, universities and industry associations will launch The Bridge Program in 2017. This is a new program focused on translating Australia’s health innovation and discovery research into the marketplace.

Expressions of Interest are now being accepted from biotech entrepreneurs, industry related professionals, research scientists and business development orientated academics, with applications due by April 28th

The Bridge Program is designed to boost the impact of Australian bioscience research by training participants in how to take their research from the lab to the market place. This industry led initiative will create commercialisation opportunities for Australia’s bioscience research sphere and Australia’s pharmaceutical and biotechnology sectors.

Participants will learn from global experts sourced from across the industry how to understand and navigate the complex regulatory, financial, scientific and intellectual property issues involved in bringing new medicines to market.

The Bridge Program will commence in June this year for 100 select participants and will also give two participants a travel scholarship to visit overseas pharmaceutical research facilities and develop global experience and business networks.

Institute of Health and Biomedical Innovation (IHBI), Executive Director, Prof Lyn Griffiths said “This program is an Australia-wide initiative that will serve as a key launching pad for researchers, entrepreneurs, academics and other industry professionals in the biotech and bioscience spheres who will now have more opportunity to take their research outputs to the patients who need them through the commercialisation path”

This program will cover 4 key modules that will provide researchers and entrepreneurs with the skills required to take their product through to the market and will involve key experts, case studies, residential training opportunities and introductions to global networks in the biotech and bioscience spheres.

David Thomson, from AbbVie, said, “This type of program capitalises on the need to connect research and industry, which is lacking in our bioscience sphere at present. In order to stay globally competitive, The Bridge Program has created opportunities for Australian science to demonstrate that it can translate into product.”

Prof Griffiths also said that, “this is a great opportunity for the bioscience ecosystem in Australia as it connects researchers, companies, entrepreneurs and other science professionals by enabling their products to get to the market and to make a difference to our health.”

Media contact details:

Kate Regnault, Email:;

Phone: +61 7 3138 5808


Apply by April 28 to be part of the Bridge Program


Institute of Health and Biomedical Innovation (IHBI)

  • Q Block
    60 Musk Avenue
    Kelvin Grove
  • Postal address:
    Institute of Health and Biomedical Innovation
    GPO Box 2434
    Brisbane QLD 4001